2022
CGRP, Migraine, and Brain MRI in CADASIL
Goldstein E, Gopal N, Badi M, Hodge D, de Havenon A, Glover P, Durham P, Huang J, Lin M, Baradaran H, Majersik J, Meschia J. CGRP, Migraine, and Brain MRI in CADASIL. The Neurologist 2022, 28: 231-236. PMID: 36729391, PMCID: PMC10277309, DOI: 10.1097/nrl.0000000000000478.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideMigraine-related disabilitySerum calcitonin gene-related peptideSerum CGRP levelsCGRP levelsBrain magnetic resonance imagingCerebral autosomal dominant arteriopathyGene-related peptideAutosomal dominant arteriopathyMagnetic resonance imagingCross-sectional analysisRadiographic associationRadiographic implicationsPrimary outcomeT2 hyperintensityCerebral microbleedsDisability ScaleSubcortical infarctsMigraine pathophysiologyVasoactive peptidesBrain MRIMigraine pathologyMigraineResonance imagingCADASILMutation of breast cancer susceptibility genes increases cerebral microbleeds: A pilot study
Pope B, Wolcott Z, Castillo M, Jin J, Wong KH, Havenon A, Yaghi S, Goldstein ED. Mutation of breast cancer susceptibility genes increases cerebral microbleeds: A pilot study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106729. PMID: 36116220, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106729.Peer-Reviewed Original ResearchConceptsCerebral small vessel diseaseCerebrovascular risk factorsBRCA mutationsCerebral microbleedsRisk factorsOdds ratioMarkers of CSVDBreast cancer susceptibility gene mutationsRetrospective cross-sectional analysisCancer susceptibility gene mutationsAdjusted odds ratioSmall vessel diseaseHosmer-Lemeshow testSusceptibility gene mutationsCross-sectional analysisLogistic regression modelsBreast cancer susceptibility genesVessel diseaseWildtype individualsBrain MRICancer susceptibility genesStudent's t-test analysisT-test analysisMalignancy evaluationClinical implications
2019
Subclinical Cerebrovascular Disease: Epidemiology and Treatment
de Havenon A, Meyer C, McNally JS, Alexander M, Chung L. Subclinical Cerebrovascular Disease: Epidemiology and Treatment. Current Atherosclerosis Reports 2019, 21: 39. PMID: 31350593, PMCID: PMC8011954, DOI: 10.1007/s11883-019-0799-1.Peer-Reviewed Original ResearchConceptsMedical managementRisk factorsAggressive medical managementSilent brain infarctsOptimal medical treatmentVascular risk factorsDevelopment of dementiaBest medical managementImportant risk factorLate-life depressionCommon clinical scenariosWhite matter hyperintensitiesT2-weighted MRISusceptibility-weighted MRIEvidence-based approachBrain infarctsCerebral microbleedsCerebrovascular diseaseGait instabilityBrain healthClinical equipoiseWorse outcomesClinical trialsMatter hyperintensitiesEpidemiologic studies